Senesco is running a Phase 1/2 study in multiple myeloma, diffuse large B-cell lymphoma and mantle cell lymphoma patients with a novel gene regulatory approach. The ability of eukaryotic translation initiation factor 5A (eIF5A) to modulate critical pathways involved in cancer and inflammatory diseases is being investigated.
Company Details
- Employees
- 3
- Founded
- -
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- senesco.com
Senesco Technologies, Inc. Questions
Senesco Technologies, Inc.'s website is senesco.com
Senesco Technologies, Inc.'s LinkedIn profile is https://www.linkedin.com/company/senesco-technologies-inc.
Senesco Technologies, Inc. has
3 employees.
View email and phone details for 3
employees at Senesco Technologies, Inc..
Senesco Technologies, Inc.'s industry is
Biotechnology Research
Senesco Technologies, Inc.'s categories are Biotechnology Research
Senesco Technologies, Inc.'s founding year is 1998
